Eight factors may predict whether a choroidal nevus -- a benign, flat, pigmented growth inside the eye and beneath the retina -- may develop into melanoma, according to a report in the August issue of Archives of Ophthalmology.
"There is strong interest for early detection of choroidal melanoma [a malignant growth], and its differentiation from nevus continues to be the major impediment," the authors write as background information in the article. Benign choroidal nevi and small melanomas share many characteristics, including color, location and size. "The challenge is to identify the single small melanoma among the thousands of choroidal nevi. It has been estimated that 6 percent of the white population harbors a choroidal nevus and that one in approximately 8,000 of these nevi transform into melanoma."
Carol L. Shields, M.D., and colleagues at Wills Eye Institute, Thomas Jefferson University, Philadelphia, studied the medical records of 2,514 consecutive eyes of patients with choroidal nevi between 1974 and 2006. The tumors had a median (midpoint) diameter of 5 millimeters and a median thickness of 1.5 millimeters at the beginning of the study. Choroidal nevi grew into melanoma in a total of 180 eyes (7 percent) over an average follow-up of 53 months, including 2 percent after one year, 9 percent after five years and 13 percent after ten years.
The factors that predicted growth into melanoma included five previously identified factors: tumor thickness greater than 2 millimeters, fluid beneath the retina, symptoms such as decreased vision or flashes and floaters, orange pigment and a tumor edge within 3 millimeters of the optic disc. Two new factors were also identified: hollowness of the growth on ultrasound and the absence of a surrounding halo, or circular band of depigmentation.
"Until systemic therapies for metastastic uveal melanoma improve, our focus should be on early detection to minimize metastastic disease," the authors write. "All ophthalmologists should participate in this effort and patients with risk factors can be referred for evaluation at centers familiar with the nuances in the diagnosis and management of early melanoma."
Patients with choroidal nevi that do not display any of the seven features of disease should be monitored twice yearly at first and then followed up yearly if their condition remains stable; those with one or two features should be monitored every four to six months; and those with three or more features should be evaluated at an experienced center for possible treatment, they conclude.
More information: Arch Ophthalmol. 2009;127:981-987.
Source: JAMA and Archives Journals (news : web)
Explore further: Enzalutamide in prostate cancer: Hints of added benefit